camrelizumab-话题@MedSci

#camrelizumab#

6篇内容 | 636人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1933608, encodeId=e4d7193360803, content=<a href='/topic/show?id=7aaa4008cb' target=_blank style='color:#2F92EE;'>#camrelizumab#</a>, objectTitle=J Immunother Cancer：中肿团队CAPTAIN研究证实国产PD-1抑制剂Camrelizumab（卡瑞利珠单抗）后线治疗复发或转移鼻咽癌疗效显著, objectType=article, longId=292765, objectId=7f53292e6591, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f53292e6591, replyNumber=0, likeNumber=43, createdTime=2022-03-12, rootId=0, userName=yangpeizhi, userId=ec25412, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f53292e6591, moduleTitle=J Immunother Cancer：中肿团队CAPTAIN研究证实国产PD-1抑制剂Camrelizumab（卡瑞利珠单抗）后线治疗复发或转移鼻咽癌疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f53292e6591)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933609, encodeId=3ea41933609ed, content=<a href='/topic/show?id=7aaa4008cb' target=_blank style='color:#2F92EE;'>#camrelizumab#</a>, objectTitle=Cancer Immunol Immunother：Camrelizumab（卡瑞利珠单抗）联合阿帕替尼和S1作为二线治疗晚期胃或胃食管交界处腺癌的疗效, objectType=article, longId=301252, objectId=1d863012523c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d863012523c, replyNumber=0, likeNumber=40, createdTime=2022-04-14, rootId=0, userName=yangpeizhi, userId=ec25412, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d863012523c, moduleTitle=Cancer Immunol Immunother：Camrelizumab（卡瑞利珠单抗）联合阿帕替尼和S1作为二线治疗晚期胃或胃食管交界处腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d863012523c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933607, encodeId=922d193360ed5, content=<a href='/topic/show?id=7aaa4008cb' target=_blank style='color:#2F92EE;'>#camrelizumab#</a>, objectTitle=Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性, objectType=article, longId=221101, objectId=e69e221101af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e69e221101af, replyNumber=0, likeNumber=48, createdTime=2022-01-07, rootId=0, userName=yangpeizhi, userId=ec25412, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e69e221101af, moduleTitle=Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e69e221101af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933606, encodeId=7bd719336061f, content=<a href='/topic/show?id=7aaa4008cb' target=_blank style='color:#2F92EE;'>#camrelizumab#</a>, objectTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, objectType=article, longId=213622, objectId=76842136220f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76842136220f, replyNumber=0, likeNumber=32, createdTime=2022-01-14, rootId=0, userName=yangpeizhi, userId=ec25412, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76842136220f, moduleTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76842136220f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933605, encodeId=d4c219336055f, content=<a href='/topic/show?id=7aaa4008cb' target=_blank style='color:#2F92EE;'>#camrelizumab#</a>, objectTitle=J Immunother Cancer：Camrelizumab联合阿帕替尼治疗晚期肝癌的效果, objectType=article, longId=208916, objectId=dc73208916ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc73208916ac, replyNumber=0, likeNumber=35, createdTime=2021-12-03, rootId=0, userName=yangpeizhi, userId=ec25412, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc73208916ac, moduleTitle=J Immunother Cancer：Camrelizumab联合阿帕替尼治疗晚期肝癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc73208916ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1933604, encodeId=60981933604e3, content=<a href='/topic/show?id=7aaa4008cb' target=_blank style='color:#2F92EE;'>#camrelizumab#</a>, objectTitle=Lancet oncol：PD-1抑制剂Camrelizumab治疗晚期肝癌患者的疗效和安全性, objectType=article, longId=189092, objectId=e4de1890923b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4de1890923b, replyNumber=0, likeNumber=44, createdTime=2020-04-18, rootId=0, userName=yangpeizhi, userId=ec25412, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4de1890923b, moduleTitle=Lancet oncol：PD-1抑制剂Camrelizumab治疗晚期肝癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4de1890923b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

camrelizumab

2020-05-29

yangpeizhi (审核中...)

前往app查看评论内容

#camrelizumab#

J Immunother Cancer：中肿团队CAPTAIN研究证实国产PD-1抑制剂Camrelizumab（卡瑞利珠单抗）后线治疗复发或转移鼻咽癌疗效显著

2022-03-12

yangpeizhi (审核中...)

前往app查看评论内容

#camrelizumab#

Cancer Immunol Immunother：Camrelizumab（卡瑞利珠单抗）联合阿帕替尼和S1作为二线治疗晚期胃或胃食管交界处腺癌的疗效

2022-04-14

yangpeizhi (审核中...)

前往app查看评论内容

#camrelizumab#

Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性

2022-01-07

yangpeizhi (审核中...)

前往app查看评论内容

#camrelizumab#

Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新

2022-01-14

yangpeizhi (审核中...)

前往app查看评论内容

#camrelizumab#

J Immunother Cancer：Camrelizumab联合阿帕替尼治疗晚期肝癌的效果

2021-12-03

yangpeizhi (审核中...)

前往app查看评论内容

#camrelizumab#

Lancet oncol：PD-1抑制剂Camrelizumab治疗晚期肝癌患者的疗效和安全性

2020-04-18

科室
- - 订阅+
  - 更多科室
工具
服务